{"product_id":"interventional-cardiology-devices-market-forecasts-to-2028-global-analysis-by-product-structural-devices-angioplasty-stents-catheters-hemodynamic-flow-alteration-devices-angioplasty-ballons-plaque-modification-devices-inferior-vena-cava-ivc-fil","title":"Interventional Cardiology Devices Market Forecasts to 2028 – Global Analysis By Product (Structural Devices, Angioplasty Stents, Catheters, Hemodynamic Flow Alteration Devices, Angioplasty Ballons, Plaque Modification Devices, Inferior Vena Cava (IVC) Fil","description":"\u003cp\u003eInterventional Cardiology Devices Market Forecasts to 2028 – Global Analysis By Product (Structural Devices, Angioplasty Stents, Catheters, Hemodynamic Flow Alteration Devices, Angioplasty Ballons, Plaque Modification Devices, Inferior Vena Cava (IVC) Filters, Other Products), End User (Ambulatory Surgical Centers, Hospitals, Other End Users) and Geography\u003cbr\u003e\nAccording to Stratistics MRC, the Global Interventional Cardiology Devices Market is accounted for $17.5 billion in 2022 and is expected to reach $30.4 billion by 2028 growing at a CAGR of 9.7% during the forecast period. Specialised equipment is needed for interventional operations in order to treat restricted arteries, damaged or weakened vessels, or other impacted areas of the heart anatomy without the need for surgery. As a result, cardiac catheterization laboratories or hospitals utilise interventional cardiology tools including coronary stents, cutting balloon catheters, and percutaneous transluminal coronary angioplasty (PTCA) to undertake minimally invasive procedures.\u003c\/p\u003e \n\n\u003cp\u003eAccording to the results published in the journal of Annals of Thoracic Surgery, 2020, approximately a 53% decrease in the total cardiac surgery volume was observed in the United States in 2020 relative to 2019, a major reason of which was the COVID-19 pandemic.\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics:\u003cbr\u003e\n \u003cbr\u003e\nDriver:\u003c\/p\u003e \n\n\u003cp\u003eRising tobacco consumption and increasing incidence of obesity\u003c\/p\u003e\n\n\u003cp\u003eCardiovascular disorders are distinctly correlated with smoking and obesity. Smoking makes blood vessels more likely to develop plaque. Smoke from cigarettes contains chemicals that make blood thicken and clot in veins and arteries. When the arteries that provide blood to the heart are constricted by plaque or clogged by clots, coronary heart disease develops. Because of this, smokers are considerably more likely than non-smokers to acquire CAD. Thus, it is anticipated that the demand for cardiovascular devices, especially interventional cardiology equipment, would rise in the coming years as a result of cigarette smoking and obesity.\u003c\/p\u003e \n\n\u003cp\u003eRestraint:\u003c\/p\u003e\n\n\u003cp\u003eComplications of Interventional Cardiology procedures\u003c\/p\u003e\n\n\u003cp\u003eBlood clots forming around the stent are known as stent thrombosis. Restenosis: The return of stenosis (abnormal arterial narrowing) following corrective surgery, and as some of the stents are metallic, an MRI scan cannot be done. The complications listed above are linked to interventional cardiac procedures. The development of the worldwide market for interventional cardiology devices is anticipated to be hampered by complications related to interventional cardiology operations.\u003c\/p\u003e \n\n\u003cp\u003eOpportunity:\u003c\/p\u003e\n\n\u003cp\u003eRising Number of Product Launches by Key Players\u003c\/p\u003e\n\n\u003cp\u003eThe leading players' increasing product introductions are projected to fuel the market for interventional cardiology devices. The significant prevalence of cardiovascular conditions including valvar defects and atrial stenosis in developing countries like China, India, and Brazil has resulted in a large need for interventional cardiology equipment for treatment. Major players are increasingly collaborating to carry out a number of clinical trials on interventional devices.\u003c\/p\u003e \n\n\u003cp\u003eThreat:\u003c\/p\u003e\n\n\u003cp\u003eStringent and complex standards\u003cbr\u003e\n \u003cbr\u003e\nThe challenging regulatory requirements for medical device affiliation are changed to accommodate shifting consumer expectations. The legal ramifications of these restrictions make them challenging. To maintain public safety, performance and quality of medical devices must be closely inspected. Therefore, the complicated and strict criteria employed to approve medical equipment may restrict market expansion.\u003c\/p\u003e \n\n\u003cp\u003eCovid-19 Impact\u003c\/p\u003e\n\n\u003cp\u003eThe market was significantly impacted by the COVID-19 epidemic. Worldwide elective surgical operations were greatly impacted by COVID-19, which also had a huge impact on the worldwide market. Treatments for structural and coronary heart disease were delayed while medical institutions battled an influx of individuals with COVID-19 infection.\u003c\/p\u003e \n\n\u003cp\u003eThe Drug Eluting Stents segment is expected to be the largest during the forecast period\u003c\/p\u003e\n\n\u003cp\u003eThe Drug Eluting Stents segment is estimated to have a lucrative growth. Drug-eluting stents are used to assist stop the development of scar tissue in the arterial lining by coating them with medicine that is gradually released. By keeping the artery smooth and wide open, this promotes healthy blood flow. These stents perform better than self-expanding \u0026amp; balloon-expanding stents and are typically utilised for the lower extremities. Therefore, it is anticipated that the acceptance of cutting-edge cardiovascular therapies and the development of drug-eluting stent technology would be the main factors driving the segment's growth. The drug-eluting stents sector is therefore anticipated to increase strongly throughout the projected period as a result of the aforementioned causes.\u003c\/p\u003e\n\n\u003cp\u003eThe Hospitals segment is expected to have the highest CAGR during the forecast period\u003c\/p\u003e\n\n\u003cp\u003eThe Hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period owing to the hospital operations have a high success rate. Less than 6% of people who have a cardiac arrest outside of a hospital survive, compared to over 200,000 cardiac arrests each year in hospitals where 24% of patients do.\u003c\/p\u003e\n\n\u003cp\u003eRegion with highest share:\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific is projected to hold the largest market share during the forecast period owing to rising consumption of unhealthy foods in emerging nations, which is predicted to accelerate the expansion of the market for interventional cardiology devices. The administrations in the area are fervently striving to organise a plethora of initiatives, programmes, and campaigns to educate the populace about cardiovascular illnesses and their impact on life in order to address the problem.\u003c\/p\u003e\n\n\u003cp\u003eRegion with highest CAGR:\u003c\/p\u003e\n\n\u003cp\u003eNorth America is projected to have the highest CAGR over the forecast period, owing to region's advanced healthcare infrastructure, supportive government product development initiatives, high patient awareness levels, and expanding target patient population. Because North America can support a high rate of medical device innovation and has a high rate of consumption of expensive interventional cardiology equipment, it dominates the market under investigation. A few significant market participants in the area are also creating innovative goods and technologies to compete with already available goods, while others are purchasing and collaborating with the other trending businesses in the industry.\u003c\/p\u003e \n\n\u003cp\u003eKey players in the market\u003c\/p\u003e\n\n\u003cp\u003eSome of the key players profiled in the Interventional Cardiology Devices Market include Philips, Merck KGAA, Thermo Fisher Scientific, Inc., Boston Scientific, Abbott, Medtronic, Edwards Lifesciences Corporation, Koninklijke Philips N.V., iVascular , Biosensors International Group , Cardinal Health and Terumo Corporation.\u003c\/p\u003e\n\n\u003cp\u003eKey Developments:\u003c\/p\u003e\n\n\u003cp\u003eIn December 2022, Boston Scientific Corporation acquired a majority of share in Acotec Scientific Holdings. The acquisition will help Boston Scientific Corporation to expand its product portfolio and market in China.\u003c\/p\u003e\n\n\u003cp\u003eIn February 2021, iVascular announced the launch of new lengths for the Angiolite drug-eluting stent (DES) for the treatment of long lesions in the coronary arteries. The 44- and 49-mm lengths received the European CE Mark approval for the treatment of diffuse lesions.\u003c\/p\u003e\n\n\u003cp\u003eProducts Covered:\u003cbr\u003e\n• Structural Devices\u003cbr\u003e\n• Guidewires\u003cbr\u003e\n• Angioplasty Stents\u003cbr\u003e\n• Catheters\u003cbr\u003e\n• Hemodynamic Flow Alteration Devices\u003cbr\u003e\n• Angioplasty Ballons\u003cbr\u003e\n• Plaque Modification Devices\u003cbr\u003e\n• Inferior Vena Cava (IVC) Filters\u003cbr\u003e\n• Accessories\u003cbr\u003e\n• Percutaneous Transluminal Coronary Angioplasty (PTCA) Guide Wires\u003cbr\u003e\n• Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons\u003cbr\u003e\n• Other Devices\u003cbr\u003e\n• Other Products\u003c\/p\u003e \n\n\u003cp\u003eEnd Users Covered:\u003cbr\u003e\n• Ambulatory Surgical Centers\u003cbr\u003e\n• Hospitals \u003cbr\u003e\n• Other End Users\u003c\/p\u003e\n\n\u003cp\u003eRegions Covered:\u003cbr\u003e\n• North America\u003cbr\u003e\nUS\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• Asia Pacific\u003cbr\u003e\nJapan\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia \u003cbr\u003e\nNew Zealand\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRest of Asia Pacific\u003cbr\u003e\n• South America\u003cbr\u003e\nArgentina\u003cbr\u003e\nBrazil\u003cbr\u003e\nChile\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Middle East \u0026amp; Africa \u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nUAE\u003cbr\u003e\nQatar\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eWhat our report offers:\u003cbr\u003e\n- Market share assessments for the regional and country-level segments\u003cbr\u003e\n- Strategic recommendations for the new entrants\u003cbr\u003e\n- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028\u003cbr\u003e\n- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)\u003cbr\u003e\n- Strategic recommendations in key business segments based on the market estimations\u003cbr\u003e\n- Competitive landscaping mapping the key common trends\u003cbr\u003e\n- Company profiling with detailed strategies, financials, and recent developments\u003cbr\u003e\n- Supply chain trends mapping the latest technological advancements\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 175 Pages \/ MCW16241328","offer_id":47657830875442,"sku":null,"price":4980.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/interventional-cardiology-devices-market-forecasts-to-2028-global-analysis-by-product-structural-devices-angioplasty-stents-catheters-hemodynamic-flow-alteration-devices-angioplasty-ballons-plaque-modification-devices-inferior-vena-cava-ivc-fil","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}